Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study

Fig. 3

Kaplan-Meier curves for progression-free survival. The median progression-free survival was 10.9 months (95% confidence interval [CI], 8.7–11.4) for PLH and 6.8 months (95% CI, 5.2–7.4) for PL (HR 0.61, 95%CI, 0.43–0.85; p = 0.001). *The hazard ratio was calculated using a Cox proportional hazards model, with the age, ECOG performance status, time since diagnosis, HCC aetiology, Child-Pugh A or B, Liver cirrhosis, PD-L1 expression, tumor thrombus, central nervous system metastasis, and number of metastatic sites used as covariates and therapy as the time-dependent factor

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us